Tarsus prices upsized $125M public offering of 2.8M shares at $44.50/share

Tarsus Pharmaceuticals, Inc.

Offering of 2,808,988 shares at public price $44.50; net proceeds ~$117.1M.
Upsized from originally proposed $100M; underwriters have 30-day option for additional 421,348 shares.
Closing expected March 14, 2025; Goldman Sachs, BofA, Barclays, Oppenheimer lead.
Offering made under effective shelf registration; use of proceeds not specified in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.